Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

BMC cancer - 12 Apr 2014

Robinson Giles W, Orr Brent A, Gajjar Amar

Abstract excerpt

BACKGROUND: Standard therapies for high grade glioma have failed to substantially improve survival and are associated with significant morbidity. At relapse, high grade gliomas, such as glioblastoma multiforme, are refractory to therapy and universally fatal. BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Glioblastoma
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Pediatrics

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24725538
DOI: 10.1186/1471-2407-14-258
PMCID: PMC3996187

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.PMID 24725538Read ↗

[Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].Semantic proximity Read ↗

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.Semantic proximity Read ↗

Integrated molecular and clinical analysis of BRAF-mutant glioma in adultsSemantic proximity Read ↗

Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.Semantic proximity Read ↗

Targeted Therapy for BRAF Mutant Brain Tumors.Semantic proximity Read ↗

Targeted therapy for BRAFV600E malignant astrocytoma.Semantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.Semantic proximity Read ↗

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade GliomasSemantic proximity Read ↗

Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.